| A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (NCT05429008) | Hutchmed | 2022-07-15 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (NCT05390528) | Shanghai Henlius Biotech | 2022-06-20 |
| A Study of PM1022 in Patients With Advanced Tumors (NCT05867771) | Biotheus Inc. | 2022-04-11 |
| Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors (NCT05213767) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2022-02-01 |
| A Study of HRS2543 in Patients With Advanced Tumors (NCT05068856) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-12-28 |
| Phase I Study of CPI-300 in Patients With Advanced Tumors (NCT04808453) | Coordination Pharmaceuticals, Inc. | 2021-06-15 |
| The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor (NCT05061628) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-21 |
| A Study of AL58805 in Patients With Advanced Tumors (NCT07179081) | Advenchen Laboratories Nanjing Ltd. | 2020-12-20 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (NCT04198818) | Haihe Biopharma Co., Ltd. | 2020-01-07 |
| Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors (NCT04151810) | Dragonboat Biopharmaceutical Company Limited | 2019-12-16 |
| Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors (NCT03908814) | Dragonboat Biopharmaceutical Company Limited | 2019-04-27 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours (NCT03697304) | Boehringer Ingelheim | 2019-03-19 |
| Study of CPI-100 in Patients With Advanced Tumors (NCT03781362) | Coordination Pharmaceuticals, Inc. | 2018-12-21 |
| Phase I Study of RiMO-301 With Radiation in Advanced Tumors (NCT03444714) | Coordination Pharmaceuticals, Inc. | 2018-04-10 |
| Study of BMS-986158 in Subjects With Select Advanced Cancers (NCT02419417) | Bristol-Myers Squibb | 2015-06-19 |